Association between race and treatment patterns and survival outcomes in multiple myeloma: A Connect MM Registry analysis
Year: 2020
Type: article
Study design: Observational Study
Abstract: BACKGROUND: Studies have reported racial disparities in access to and use of multiple myeloma (MM) treatments between African American (AA) and White patients. Although AA patients demonstrate longer disease-specific survival, this has not uniformly translated into improved survival over time. The association between race and treatment patterns and survival outcomes was analyzed using data from the Connect MM Registry. METHODS: The Connect MM Registry is a large US, multicenter, prospective observational cohort study of patients with newly diagnosed MM. Patients who received first-line (1L) stem cell transplantation (SCT) or who did not receive SCT (non-SCT or non-stem cell transplantation [NSCT]) were grouped by raceEffects of race and transplantation status on the use of triplet treatment were estimated using logistic regression. RESULTS: Treatment patterns in 1L (types and duration of induction, posttransplantation maintenance) were similar between AA and White patients. SCT rates in 1L (32% vs 36%) and triplet treatment use (AA: 44% for NSCT patients and 72% for SCT patients; and White: 48% for NSCT patients and 72% for SCT patients) during first induction were similar. No significant effect of race or transplantation status on 1L triplet treatment use was observed. Race was not found to be associated with survival outcomes among patients who underwent NSCT; however, AA patients who received SCT had significantly longer overall survival compared with White patients who underwent SCT (not reached vs 88.2 months; hazard ratio, 0.56; 95% CI, 0.35-0.89 [P = .0141]). CONCLUSIONS: AA and White patients were found to have similar treatment patterns in the Connect MM Registry, suggesting that both groups had equal access to health care. In this real-world setting, AA patients received standard-of-care treatment, which might have contributed to better MM-specific survival compared with White patients.
Source: Cancer
DOI: 10.1002/cncr.33089
Authors: Sikander Ailawadhi, Sundar Jagannath, Hans C. Lee, Mohit Narang, Robert M. Rifkin, Howard R. Terebelo, Brian G. M. Durie, Kathleen Toomey, James W. Hardin, Cristina J. Gasparetto, Lynne Wagner, James L. Omel, Mia He, Lihua Yue, Elizabeth Dawn Flick, Amit Agarwal, Rafat Abonour, Connect MM Registry Investigators
Institutions: Mayo Clinic, Mayo Clinic in Florida, Mount Sinai Hospital, The University of Texas MD Anderson Cancer Center, Rocky Mountain Cancer Centers, Cedars-Sinai Medical Center, Somerville Hospital, University of South Carolina, Duke Medical Center, Wake Forest University Health Sciences, Wake Forest University, Bristol-Myers Squibb (United States), Indiana University Indianapolis
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,200
Funders: Amgen, Bristol-Myers Squibb, AstraZeneca, GlaxoSmithKline, Sanofi, Gilead Sciences, Celgene, Karyopharm Therapeutics, Prothena, Adaptive Biotechnologies, Myriad Genetics, Ascentage Pharma, EMD Serono, Takeda Oncology, Pharmacyclics, National Cancer Institute, Janssen Pharmaceuticals, Daiichi Sankyo Europe
Award: G1016754749
OpenAlex ID: W3044259272